Stock Monitor: ConforMIS Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors.com has just released a free research report on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BDX as the Company's latest news hit the wire. On February 13, 2018, the Company, which is one of the largest global medical technology organizations in the world, declared that it has received pre-market approval from the US Food and Drug Administration (FDA) for its new human papillomavirus (HPV) Test, BD Onclarity™ HPV assay. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for ConforMIS, Inc. (NASDAQ: CFMS), which also belongs to the Healthcare sector as the Company Becton, Dickinson. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Becton, Dickinson most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
The FDA's approval is based on the data collected during a multi-year, prospective, multi-center clinical trial, which was conducted in the US and enrolled over 33,500 vaccinated and non-vaccinated women.
Cervical Cancer Can be Prevented by Early Screening
Cervical cancer is a malignant tumor of the cervix, which is the lowermost part of the uterus. Cervical cancer is the second most common type of cancer for women worldwide. Most of the cervical cancer cases are caused by HPV.
Cervical cancer is also one of the most preventable types of cancer as it develops over time. Cervical screening, through Pap test and HPV test, help prevent cervical cancer. Pap tests do not detect cancer but can disclose any cell changes that indicate that the cancer could develop, so that timely action can be taken. On the other hand, the HPV test checks for a high-risk HPV infection in women. A Pap test can be done during a pelvic exam and an HPV test can be done on the same sample of cells collected from the Pap test.
Working of the BD Onclarity™ HPV Assay
The BD Onclarity™ HPV assay test identifies 14 distinct types of high-risk HPV from specimens collected for cervical cancer screening in the BD SurePath™ liquid-based Pap test. The BD Onclarity™ HPV assay recognizes HPV genotypes 16, 18, and 45, which are related to most of the cervical cancers worldwide. In fact, HPV genotypes 16, 18, and 45 are disproportionally responsible for about 94% of glandular cervical cancer cases.
This test has been clinically approved for use as a primary screening test for triaging patients with abnormal Pap test results. It has also been validated for use in combination with a Pap test. However, physicians must use this test in accordance with clinical guidelines for cervical cancer screening and management.
The BD Onclarity™ HPV assay is performed on the BD Viper LT system, which is a bench top molecular platform that automates sample processing. The BD Viper LT system has been approved by the FDA for chlamydia and/or gonorrhea infection (CT/GC) testing.
BD Onclarity™ HPV Assay Aids Clinical Decision-Making
Information provided by the BD Onclarity™ HPV assay, along with physicians' assessment and professional guidelines, can facilitate informed clinical decision-making. The BD Onclarity™ test is in-line with the clinical screening guidelines from the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. Its approval would provide clinicians and laboratories an FDA-approved option for HPV primary screening, which is perfectly compatible with the BD SurePath™ liquid-based cytology vial. Thus, it signifies the next milestone in cervical cancer screening.
Dave Hickey, President at BD Diagnostics Systems, shared that BD aims to provide comprehensive cervical cancer screening solutions to laboratories and clinicians worldwide. These solutions would address the unique needs of individual healthcare providers as well as patients. The approval of BD Onclarity™ HPV assay would also help BD enhance the standard of care for cervical cancer patients worldwide.
Status in Global Markets
The BD Onclarity™ HPV assay achieved the European CE-IVD mark in 2014. It also received the regulatory approval in Canada and Japan in 2017. At present, the test is available for sale in these regions and other markets.
Future Plans for BD Onclarity™ HPV Assay
BD further plans to seek the FDA's approval for the reporting of HPV types beyond 16, 18, and 45. This is in-line with the extended genotyping capabilities of BD Onclarity™ HPV assay, and is also consistent with the evolving cervical cancer screening guidelines.
Stock Performance Snapshot
February 14, 2018 - At Wednesday's closing bell, Becton, Dickinson's stock rose 2.11%, ending the trading session at $219.95.
Volume traded for the day: 1.32 million shares.
Stock performance in the previous six-month period - up 9.17%; past twelve-month period - up 23.04%; and year-to-date - up 2.75%
After yesterday's close, Becton, Dickinson's market cap was at $49.13 billion.
Price to Earnings (P/E) ratio was at 167.26.
The stock has a dividend yield of 1.36%.
The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was up 1.4% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.